Molecular Markers in Predicting Response to Treatment in FH-deficient RCC

Status Recruiting

Clinical Trial Summary

Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare subtype of RCC characterized by germline/somatic mutation of the fumarate hydratase (FH) gene, and is an extremely aggressive tumor, with a propensity to disseminate early even in the setting of a small primary tumor. This project is a real-world exploratory study aiming to explore potential molecular markers detectable at baseline that can enable the prediction of clinical efficacy of systemic treatments in advanced FH-deficient RCC. This project is a real-world exploratory study aiming to explore potential molecular markers detectable at baseline that can enable the prediction of clinical efficacy of immunotherapy combined with target therapy in advanced FH-deficient RCC. This study aims to include a total of 100 patients initially diagnosed with advanced FH-deficient RCC. Paired tissue and blood samples collected from all patients before or/ and after the start of immunotherapy-based treatment (at diagnosis or/ and their change with treatment) will be analyzed. The patient samples will be submitted for molecular analysis, including next-generation sequencing (NGS)-based gene expression profiling (GEP), RNA-sequencing, multiplex immunofluorescence staining and inflammation-related T-cell receptor (TCR) repertoire profiling, ect. The molecular assay results will include but will not be limited to tumor mutation burden (TMB), microsatellite instability (MSI) status, DNA damage repair (DDR)-related gene mutation status, and programmed death-ligand 1 (PD-L1) expression level. Patients will be followed-up for treatment responses until radiological confirmation of disease progression to immunotherapy-based treatment. The molecular assay results will then be analyzed with clinical data including objective responses and progression-free survival outcomes, among others, to identify molecular markers at baseline that are associated with clinical efficacy of immunotherapy-based treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Biomarkers

Clinical Trial Details

NCT number	NCT05535829
Study type	Observational
Source	RenJi Hospital
Contact	Yunze Xu
Phone	+8618801967501
Email	xuyunze@renji.com
Status	Recruiting
Phase
Start date	August 1, 2022
Completion date	December 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05095324` - The Biomarker Prediction Model of Septic Risk in Infected Patients
Recruiting	`NCT05548933` - Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia
Active, not recruiting	`NCT03926572` - Acute Decompensation of Pulmonary Hypertension	N/A
Recruiting	`NCT05372159` - Vanderbilt Memory and Aging Project
Completed	`NCT03173586` - Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women	N/A
Completed	`NCT04554628` - Early Prediction of Acute Kidney Injury Among Patients Admitted to Surgical ICU	N/A
Terminated	`NCT03250312` - The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers	N/A
Recruiting	`NCT04666766` - Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers	N/A
Completed	`NCT04573543` - The Role of Immune Semaphorins in NAFLD
Completed	`NCT03193671` - Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis	N/A
Recruiting	`NCT06047132` - PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS
Completed	`NCT05361460` - Patients Experiences of Early Postoperative Cognition
Recruiting	`NCT05706194` - Early Neuroprognostication After OHCA
Recruiting	`NCT05138731` - Metabolomics Profiling of Coronary Heart Disease
Recruiting	`NCT06446895` - Biomarkers of Inflammation and Endothelial Dysfunction in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries
Not yet recruiting	`NCT04563000` - Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest	Phase 2
Completed	`NCT05138692` - Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury
Completed	`NCT02247999` - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Active, not recruiting	`NCT02732301` - Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers
Not yet recruiting	`NCT03269019` - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms